Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials

Breast - Advanced ER (+) HER2 (-)

Monarch 3 (I3Y-MC-JPBM)

A randomized, double-blind, placebo-controlled, phase III study of nonsteroidal aromatase inhibitors (anastrozole or letrozole) plus LY2835219, a CDK4/6 inhibitor, or placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting.

Breast - Early Stage - Vaccine

PRESENT

Prevention of recurrence in early-stage, node-positive breast cancer with low to intermediate HER2 expression with NeuVaxTM treatment.

Breast - Metastatic, BRCA 1 and BRCA 2

Brocade 3 (M12-914)

A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.

www.Brocade3Study.com

Breast - Operable, HER2 (+)

Kaitlin (BO24807)

A randomized, multicenter, open-label, phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

Breast Registry

Nipple Sparing

ASBrS Nipple Sparing Mastectomy Registry.

Breast, Triple-Negative

LOTUS (GO29277)

A randomized, phase II, multicenter placebo-controlled study of ipatasertib (GDC-0068), an inhibitor of AKT, in combination with paclitaxel as front-line treatment for patients with metastatic triple-negative breast cancer.

Colorectal - Advanced

Pfizer B2151007

An open-label, multi-center, randomized phase 1B/2 study of PF-05212384 (PI3K inhibitor) plus 5-Fluorouracil-Leucovorin-Iriniotecan (FOLFIRI) versus Bevacizumab plus FOLFIRI in metastatic colorectal cancer.

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives

Iron Deficiency Anemia

PROVIDE

A phase III, randomized, open-label, comparative study of intravenous iron isomaltoside 1000 (Monofer®) and iron sucrose in subjects with iron deficiency anemia and who are intolerant or unresponsive to oral iron therapy or who need iron rapidly.

Lung - Metastatic

M11-089

Randomized, double blind, multicenter, phase III study comparing veliparib (ABT-888) plus carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in previously untreated advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukemia (AML)

Connect® MDS and AML Registry

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

Solid Tumors (Metastatic Gastric, Melanoma, Mesothelioma or Urothelial Cancers) - Advanced

Merck EMR 100070-001

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biolocial and clinical activity of MSB0010718C (PD-L1 inhibitor) in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.

Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.

Directions

image description